

<b>Όνοματεπώνυμο:</b>	<b>TENTES ΙΩΑΝΝΗΣ</b>
<b>Όνομα πατρός:</b>	KIMΩΝ
<b>Όνομα μητρός:</b>	ΔΗΜΗΤΡΑ
<b>Έτος γεννήσεως:</b>	1960
<b>Τόπος γεννήσεως:</b>	ΑΛΕΞΑΝΔΡΟΥΠΟΛΗ
<b>Οικογενειακή κατάσταση:</b>	Παντρεμένος, πατέρας δύο παιδιών
<b>Διεύθυνση εργασίας:</b>	Δημοκρίτειο Πανεπιστήμιο Θράκης, Τμήμα Ιατρικής, Εργαστήριο Βιοχημείας, 68100 Αλεξανδρούπολη
<b>Επικοινωνία:</b>	Τηλ +3025510 30531, Fax: +3025510 30502, κινητό : +306979327850, e-mail: itentes@med.duth.gr
<b>Ξένες Γλώσσες:</b>	Αγγλικά

#### Πανεπιστημιακή εκπαίδευση:

1985-1987	<b>Salford University (Manchester, U.K), Βιοχημικό Τμήμα : PhD</b> στη Βιοχημεία.
1983-1985	<b>Salford University (Manchester, U.K), Βιοχημικό Τμήμα : MSc</b> στη Βιοχημεία.
1980-1983	<b>Salford University (Manchester, U.K), Βιοχημικό Τμήμα : BSc</b> στη Βιοχημεία

#### ΠΡΟΫΠΗΡΕΣΙΑ

2018-	Καθηγητής Βιοχημείας, Τμ. Ιατρικής ΔΠΘ
2008-2018	Αναπληρωτής καθηγητής Βιοχημείας, Τμ. Ιατρικής ΔΠΘ
2003-2008	Μόνιμος Επίκουρος Καθηγητής Βιοχημείας, Τμ. Ιατρικής, Δ.Π.Θράκης
1999-2003	Επίκουρος Καθηγητής Βιοχημείας, Τμ. Ιατρικής, Δ.Π.Θράκης
1993-1999	Λέκτορας Βιοχημείας, Τμ. Ιατρικής Δ.Π.Θράκης
1990-1993	Μεταδιδακτορικός Υπότροφος (Ινστιτούτο Μοριακής Βιολογίας και Βιοτεχνολογίας), Ηράκλειο, Κρήτη.

#### ΕΡΕΥΝΗΤΙΚΑ ΕΝΔΙΑΦΕΡΟΝΤΑ

- Μοριακοί μηχανισμοί που ορίζουν τη δυναμική της αθηροσκλήρωσης και άλλων νόσων με μεταβολική αιτιολογία.
- Καρκινογένεση .
- Οξειδωτικό stress -Απόπτωση.
- Κυτταρική σηματοδότηση.
- Κλασική Βιοχημεία/Πρωτεϊνοχημεία/Λιπιδωμική έρευνα.

#### ΔΙΟΙΚΗΤΙΚΗ ΕΜΠΕΙΡΙΑ

- Διευθυντής του Εργαστηρίου Βιοχημείας του Τμ. Ιατρικής ΔΠΘ από τον Μάρτιο 2016.
- Διευθυντής του Λειτουργικού- Κλινικοεργαστηριακού Τομέα του Τμ. Ιατρικής Δ.Π.Θ. επί τρεις θητείες (από 2021 έως 2022, από 2022 έως 2023 και από 2023 έως 2025).

- Αναπληρωτής ΕΥ του ΜΠΣ «Βιοϊατρικές Επιστήμες στη διάγνωση και θεραπεία της νόσου».
- Μέλος της επιτροπής προγράμματος σπουδών και επιλογής υποψηφίων του ΜΠΣ «Κλινική Φαρμακολογία – Θεραπευτική».
- Μέλος της επιτροπής προγράμματος σπουδών και επιλογής υποψηφίων του ΜΠΣ «Λοιμώδη Νοσήματα Διεθνής Ιατρική από το Εργαστήριο στην Κλινική Πράξη»

#### **ΣΥΜΜΕΤΟΧΗ ΣΕ ΧΡΗΜΑΤΟΔΟΤΟΥΜΕΝΑ ΠΡΟΓΡΑΜΜΑΤΑ**

- **ΤΙΤΛΟΣ:** Ανάπτυξη καινοτόμων αλεύρων, προζυμιών και αρτοσκευασμάτων με στόχο την πρόληψη χρόνιων ασθενειών και τη βελτίωση της ποιότητας ζωής  
**ΑΚΡΩΝΥΜΙΟ: ΣΙΤΩ (ΣΙΤΟ) ΚΩΔΙΚΟΣ ΕΡΓΟΥ : 82147**
- **ΙΔΙΟΤΗΤΑ :** Επιστημονικά Υπεύθυνος
- **ΠΡΟΫΠΟΛΟΓΙΣΜΟΣ :** Για το σύνολο του Έργου : 993.844,00, για το Τμ. Ιατρικής ΔΠΘ : €143.282,50 €
- **ΔΡΑΣΗ ΕΘΝΙΚΗΣ ΕΜΒΕΛΕΙΑΣ: «ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ»**  
Ειδική Υπηρεσία Διαχείρισης Επιχειρησιακού Προγράμματος Ανταγωνιστικότητα, Επιχειρηματικότητα και Καινοτομία (ΕΥΔ ΕΠΑνΕΚ). Ειδική Υπηρεσία Διαχείρισης και Εφαρμογής Δράσεων στους τομείς Έρευνας, Τεχνολογικής Ανάπτυξης και Καινοτομίας(ΕΥΔΕ ΕΤΑΚ)  
Από : 25/07/2018 έως : 27/06/2021.

#### **ΔΗΜΟΣΙΕΥΣΕΙΣ**

**Αριθμός εργασιών : 68**

**Citations : 1.536**

**Impact factor : 185**

**h-index : 23**

1. Correlation between the in vitro starch digestibility and the glycemic/insulinemic index of biscuits and bread made from non-conventional wholemeal/wholegrain flours. Papadopoulos, C., Anagnostopoulos, C., Zisimopoulos, A., ...Tente, T., Tentes, I. Mediterranean Journal of Nutrition and Metabolism, 2023, 16(3), pp. 165–180
2. Red Blood Cell Malfunction in COVID-19: Molecular Mechanisms and Therapeutic Targets. Papadopoulos, C., Spourita, E., Tentes, I., Steiropoulos, P., Anagnostopoulos, K. Viral Immunology, 2022, 35(10), pp. 649–652
3. Lysophospholipid Metabolism and Signalling in Non-Alcoholic Fatty Liver Disease |. Papadopoulos, C., Tentes, I., Papazoglou, D., Anagnostopoulos, K. Folia Medica, 2022, 64(1), pp. 7–12
4. Red Blood Cell-Conditioned Media from Non-Alcoholic Fatty Liver Disease Patients Contain Increased MCP1 and Induce TNF- $\alpha$  Release. Papadopoulos, C., Mimidis, K., Papazoglou, D.,... Tentes, I., Anagnostopoulos, K. Reports of Biochemistry and Molecular Biology, 2022, 11(1), pp. 54–62
5. Validation and application of a protocol for the extraction and quantitative analysis of sphingomyelin in erythrocyte membranes of patients with non-alcoholic fatty liver disease Papadopoulos, C., Mimidis, K., Tentes, I., Tente, T., Anagnostopoulos, K. Journal of Planar Chromatography - Modern TLC, 2021, 34(5), pp. 411–418
6. Lipotoxicity Disrupts Erythrocyte Function: A Perspective. Papadopoulos, C., Tentes, I., Anagnostopoulos, K. Cardiovascular and Hematological Disorders - Drug Targets, 2021, 21(2), pp. 91–94
7. Immune and metabolic interactions of human erythrocytes: A molecular perspective. Papadopoulos, C., Panopoulou, M., Anagnostopoulos, K., Tentes, I. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21(5), pp. 843–853
8. Correlation of Baseline Plasma and Inguinal Connective Tissue Metalloproteinases and Their Inhibitors With Late High-Pressure Endoleak After Endovascular Aneurysm Repair: Long-term Results. Georgiadis GS, Antoniou GA, Argyriou C, Schoretzanitis N, Nikolopoulos E, Kapoulas K, Lazarides MK, Tentes I.J Endovasc Ther. 2019 Dec;26(6):826-835. doi: 10.1177/1526602819871963. Epub 2019 Aug 29.
9. Gut Microbial Signatures Underline Complicated Crohn's Disease but Vary Between Cohorts; An In Silico Approach. Dovrolis N, Drygiannakis I, Filidou E, Kandilogiannakis L,

- Arvanitidis K, Tentes I, Kolios G, Valatas V. *Inflamm Bowel Dis*. 2019 Jan 10;25(2):217-225. doi: 10.1093/ibd/izy328.
10. Retrobulbar hemodynamics and aqueous humor levels of endothelin-1 in exfoliation syndrome and exfoliation glaucoma. Koukoulou SC, Katsanos A, Tentes IK, Labiris G, Kozobolis VP. *Clin Ophthalmol*. 2018 Jul 2;12:1199-1204. doi: 10.2147/OPTH.S155551. eCollection 2018.
  11. Intravasation of SW620 colon cancer cell spheroids through the blood endothelial barrier is inhibited by clinical drugs and flavonoids in vitro. Holzner S, Brenner S, Atanasov AG, Senfter D, Stadler S, Nguyen CH, Fristiohady A, Milovanovic D, Huttary N, Krieger S, Bago-Horvath Z, de Wever O, Tentes I, Özmen A, Jäger W, Dolznig H, Dirsch VM, Mader RM, Krenn L, Krupitza G. *Food Chem Toxicol*. 2018 Jan;111:114-124. doi: 10.1016/j.fct.2017.11.015. Epub 2017 Nov 10.
  12. Prepartum Psychosis and Neonaticide: Rare Case Study and Forensic-Psychiatric Synthesis of Literature. Karakasi MV, Markopoulou M, Tentes IK, Tsikouras PN, Vasilikos E, Pavlidis P. *J Forensic Sci*. 2017 Jul;62(4):1097-1106. doi: 10.1111/1556-4029.13365. Epub 2017 Jun 5. Review.
  13. Room air versus carbon dioxide pneumoperitoneum: effects on oxidative state, apoptosis and histology of splanchnic organs. Ypsilantis P1, Lambropoulou M2, Tentes I3, Chryssidou M4, Georgantas T4, Simopoulos C4. *Surg Endosc*. 2016 Apr; 30 (4) : 1388 - 95. doi: 10.1007/s00464-015-4341-4. Epub 2015 Jun 27.
  14. Regional disparities in cancer mortality across the rural-urban axis: a case study from north-eastern Greece. Nikolaidis C1, Tentes I2, Lialiaris T3, Constantinidis TC4, Kortsaris A5. *Rural Remote Health*. 2015 Jul-Sep;15(3):3013. Epub 2015 Aug 7.
  15. Assessment of Interleukins IL-4, IL-6, IL-8, IL-10 in Acute Urticaria. Papadopoulos J, Karpouzis A, Tentes J, Kouskoukis C. *J Clin Med Res*. 2014 Apr;6(2):133-7.
  16. Tissue inhibitor of metalloproteinase 4 in aqueous humor of patients with primary open angle glaucoma, pseudoexfoliation syndrome and pseudoexfoliative glaucoma and its role in proteolysis imbalance. Fountoulakis N, Labiris G, Aristeidou A, Katsanos A, Tentes I, Kortsaris A, Kozobolis VP. *BMC Ophthalmol*. 2013 Nov 8;13:693.
  17. Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF- $\alpha$  and TGF- $\beta$ 1. Tripsianis G, Papadopoulou E, Romanidis K, Katotomichelakis M, Anagnostopoulos K, Kontomanolis E, Botaitis S, Tentes I, Kortsaris A. *Asian Pac J Cancer Prev*. 2013;14(11):6813-20.
  18. Coexpression of IL-6 and TNF- $\alpha$ : prognostic significance on breast cancer outcome. Tripsianis G, Papadopoulou E, Anagnostopoulos K, Botaitis S, Katotomichelakis M, Romanidis K, Kontomanolis E, Tentes I, Kortsaris A. *Neoplasma*. 2014;61(2):205-12.
  19. Erythrocyte membrane cholesterol and lipid core growth in a rabbit model of atherosclerosis: modulatory effects of rosuvastatin. Tziakas D, Chalikias G, Kapelouzou A, Tentes I, Schäfer K, Karayannakos P, Kostakis A, Boudoulas H, Konstantinides S. *Int J Cardiol*. 2013 Dec 10;170(2):173-81.
  20. Lipopolysaccharide-binding protein: a potential marker of febrile urinary tract infection in childhood. Tsalkidou EA, Roilides E, Gardikis S, Trypsianis G, Kortsaris A, Chatzimichael A, Tentes I. *Pediatr Nephrol*. 2013 Jul;28(7):1091-7. Silibinin protects H9c2 cardiac cells from oxidative stress and inhibits phenylephrine-induced hypertrophy: potential mechanisms.
  21. Anestopoulos I, Kavo A, Tentes I, Kortsaris A, Panayiotidis M, Lazou A, Pappa A. *J Nutr Biochem*. 2013 Mar;24(3):586-94. Red blood cell distribution width: a strong prognostic marker in cardiovascular disease: is associated with cholesterol content of erythrocyte membrane. Tziakas D, Chalikias G, Grapsa A, Gioka T, Tentes I, Konstantinides S. *Clin Hemorheol Microcirc*. 2012;51(4):243-54.
  22. Phenotype and genotype frequency of  $\beta$ -thalassemia and sickle cell disease carriers in Halkidiki, Northern Greece. Kalleas C, Anagnostopoulos K, Sinopoulou K, Delaki E, Margaritis D, Bourikas G, Tsatalas C, Kortsaris A, Tentes I. *Hemoglobin*. 2012;36(1):64-72
  23. Matrix metalloproteinase imbalance in inguinal hernia formation. Antoniou GA, Tentes IK, Antoniou SA, Simopoulos C, Lazarides MK. *J Invest Surg*. 2011;24(4):145-50. Circulating matrix metalloproteinases and their inhibitors in inguinal hernia and abdominal aortic aneurysm.
  24. Antoniou GA, Tentes IK, Antoniou SA, Georgiadis GS, Giannoukas AD, Simopoulos C, Lazarides MK. *Int Angiol*. 2011 Apr;30(2):123-9.

25. Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer. Koukourakis MI, Limberis V, Tentes I, Kontomanolis E, Kortsaris A, Sivridis E, Giatromanolaki A. *Cytokine*. 2011 Mar;53(3):370-5. Pringle maneuver deteriorates gut barrier dysfunction induced by extended-liver radiofrequency ablation.
26. Ypsilantis P, Lambropoulou M, Grapsa A, Tentes I, Tsigalou C, Panopoulou M, Simopoulos C. *Dig Dis Sci*. 2011 May;56(5):1548-56. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A. *Int J Biol Markers*. 2010 Jul-Sep;25(3):126-35.
27. Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620. Tentes IK, Schmidt WM, Krupitza G, Steger GG, Mikulits W, Kortsaris A, Mader RM. *Exp Cell Res*. 2010 Nov 15;316(19):3172-81.
28. Independent and additive predictive value of total cholesterol content of erythrocyte membranes with regard to coronary artery disease clinical presentation. Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Papazoglou D, Thomaidi A, Grapsa A, Gioka G, Kaski JC, Boudoulas H. *Int J Cardiol*. 2011 Jul 1;150(1):22-7
29. Mesna preserves hepatocyte regenerating capacity following liver radiofrequency ablation under Pringle maneuver. Ypsilantis P, Lambropoulou M, Anagnostopoulos C, Tentes I, Tsigalou C, Pitiakoudis M, Kortsaris A, Papadopoulos N, Simopoulos C. *J Surg Res*. 2011 Jul;169(1):44-50. Chromosome instability on children with asthma.
30. Lialiaris T, Polyzou A, Mpountoukas P, Tsiggene A, Kouskoulis A, Pouliliou S, Paraskakis E, Tentes I, Tripsianis G, Chatzimichail A. *J Asthma*. 2009 Oct;46(8):841-4.
31. Statin use is associated with a significant reduction in cholesterol content of erythrocyte membranes. A novel pleiotropic effect? Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Thomaidi A, Chatzikiyiakou S, Mitrousi K, Kortsaris AX, Kaski JC, Boudoulas H, Konstantinides S. *Cardiovasc Drugs Ther*. 2009 Dec;23(6):471-80.
32. Total cholesterol content of erythrocyte membranes and coronary atherosclerosis: an intravascular ultrasound pilot study. Giannoglou GD, Koskinas KC, Tziakas DN, Ziakas AG, Antoniadis AP, Tentes IK, Parcharidis GE. *Angiology*. 2009 Dec-2010 Jan;60(6):676-82
33. Statin use is associated with a significant reduction in cholesterol content of erythrocyte membranes. A novel pleiotropic effect? Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Thomaidi A, Chatzikiyiakou S, Mitrousi K, Kortsaris AX, Kaski JC, Boudoulas H, Konstantinides S. *Cardiovasc Drugs Ther*. 2009 Dec;23(6):471-80.
34. Total cholesterol content of erythrocyte membranes and coronary atherosclerosis: an intravascular ultrasound pilot study. Giannoglou GD, Koskinas KC, Tziakas DN, Ziakas AG, Antoniadis AP, Tentes IK, Parcharidis GE. *Angiology*. 2009 Dec-2010 Jan;60(6):676-82.
35. Bacterial translocation in a rat model of large volume hepatic radiofrequency ablation. Ypsilantis P, Panopoulou M, Lambropoulou M, Tsigalou C, Pitiakoudis M, Tentes I, Kartali S, Papachristou F, Papadopoulos N, Simopoulos C. *J Surg Res*. 2010 Jun 15;161(2):250-8.
36. Impaired liver regeneration following partial hepatectomy using the Pringle maneuver: Protective effect of mesna. Ypsilantis P, Lambropoulou M, Tentes I, Anagnostopoulos K, Tsigalou C, Papadopoulos N, Kortsaris A, Simopoulos C. *J Gastroenterol Hepatol*. 2009 Apr;24(4):623-32.
37. Cholesterol composition of erythrocyte membranes and its association with clinical presentation of coronary artery disease. Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Chatzikiyiakou SV, Mitrousi K, Kortsaris AX, Boudoulas H, Kaski JC. *Coron Artery Dis*. 2008 Dec;19(8):583-90
38. Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome. Tziakas DN, Chalikias GK, Tentes IK, Stakos D, Chatzikiyiakou SV, Mitrousi K, Kortsaris AX, Kaski JC, Boudoulas H. *Eur Heart J*. 2008 Nov;29(22):2713-22
39. Cell signaling in cancer. Anagnostopoulos K, Tentes I, Kortsaris AH. *J BUON*. 2008 Jan-Mar;13(1):17-22. Review.

40. Mesna protects splanchnic organs from oxidative stress induced by pneumoperitoneum. Ypsilantis P, Tentes I, Anagnostopoulos K, Kortsaris A, Simopoulos C. *Surg Endosc*. 2009 Mar;23(3):583-9.
41. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism. Papadopoulou E, Anagnostopoulos K, Tripsianis G, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A. *Neoplasma*. 2008;55(3):229-38.
42. Stilbene analogues affect cell cycle progression and apoptosis independently of each other in an MCF-7 array of clones with distinct genetic and chemoresistant backgrounds. Bader Y, Madlener S, Strasser S, Maier S, Saiko P, Stark N, Popescu R, Huber D, Gollinger M, Erker T, Handler N, Szakmary A, Jäger W, Kopp B, Tentes I, Fritzer-Szekeres M, Krupitza G, Szekeres T. *Oncol Rep*. 2008 Mar;19(3):801-10.
43. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Papadopoulou E, Simopoulos K, Tripsianis G, Tentes I, Anagnostopoulos K, Sivridis E, Galazios G, Kortsaris A. *Neoplasma*. 2007;54(5):365-73.
44. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A. *Neoplasma*. 2008;55(2):113-21.
45. Prophylaxis with mesna prevents oxidative stress induced by ischemia reperfusion in the intestine via inhibition of nuclear factor-kappaB activation. Ypsilantis P, Tentes I, Lambropoulou M, Anagnostopoulos K, Papadopoulos N, Kortsaris A, Simopoulos C. *J Gastroenterol Hepatol*. 2008 Feb;23(2):328-35.
46. Matrix metalloproteinase (MMP)-2 and MMP-9 in seminal plasma. Tentes I, Asimakopoulos B, Mourvati E, Diedrich K, Al-Hasani S, Nikolettos N. *J Assist Reprod Genet*. 2007 Jul;24(7):278-81.
47. Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? Tziakas DN, Kaski JC, Chalikias GK, Romero C, Fredericks S, Tentes IK, Kortsaris AX, Hatseras DI, Holt DW. *J Am Coll Cardiol*. 2007 May 29;49(21):2081-9.
48. Effect of HbS in the determination of HbA2 with the Biorad Variant II analyzer. Kalleas C, Tentes I, Margaritis D, Anagnostopoulos K, Toli A, Pendilas D, Bourikas G, Tsatalas C, Kortsaris AH. *Clin Biochem*. 2007 Jun;40(9-10):744-6.
49. Effect of HbS in the determination of HbA(2) with the TOSOH HLC-723G7 analyzer and the HELENA Beta-Thal Quik column kit. Kalleas C, Tentes I, Margaritis D, Anagnostopoulos K, Toli A, Pendilas D, Bourikas G, Tsatalas C, Kortsaris AH. *Clin Biochem*. 2007 Feb;40(3-4):242-7.
50. Apolipoprotein E genotype and circulating interleukin-10 levels in patients with stable and unstable coronary artery disease. Tziakas DN, Chalikias GK, Antonoglou CO, Veletza S, Tentes IK, Kortsaris AX, Hatseras DI, Kaski JC. *J Am Coll Cardiol*. 2006 Dec 19;48(12):2471-81.
51. Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. Chalikias GK, Tziakas DN, Kaski JC, Kekes A, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris AX, Hatseras DI. *Int J Cardiol*. 2007 May 2;117(3):333-9.
52. Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. Tziakas DN, Chalikias GK, Kaski JC, Kekes A, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris AX, Hatseras DI. *Atherosclerosis*. 2007 Jul;193(1):196-203.
53. Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer. Tentes AA, Markakidis SK, Karanikiotis C, Fiska A, Tentes IK, Manolopoulos VG, Dimitriou T. *Langenbecks Arch Surg*. 2006 Apr;391(2):124-9.
54. Mesna protects intestinal mucosa from ischemia/reperfusion injury. Ypsilantis P, Lambropoulou M, Tentes I, Kortsaris A, Papadopoulos N, Simopoulos C. *J Surg Res*. 2006 Aug;134(2):278-84.
55. Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure. Tziakas DN, Chalikias GK, Hatzinikolaou HI, Stakos DA, Papanas N, Tentes IK, Kortsaris AX, Maltezos E, Hatseras DI, Kaski JC. *Cardiovasc Drugs Ther*. 2005 Dec;19(6):399-402.

56. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Tziakas DN, Chalikias GK, Papaioakeim M, Hatzinikolaou EI, Stakos DA, Tentes IK, Papanas N, Kortsaris A, Maltezos E, Hatseras DI. *Am J Cardiol.* 2005 Nov 15;96(10):1449-51
57. Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI, Kaski JC. *Thromb Res.* 2006;118(2):221-7.
58. Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Chalikias GK, Tziakas DN, Kaski JC, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI. *Atherosclerosis.* 2005 Sep;182(1):135-43. Epub 2005 Feb 26.
59. Gelatinases [matrix metalloproteinase-2 (MMP-2) and MMP-9] induce carotid plaque instability but their systemic levels are not predictive of local events. Tziakas DN, Lazarides MK, Tentes IK, Georgiadis GS, Eleftheriadou E, Chalikias GK, Kortsaris A, Hatseras DI. *Ann Vasc Surg.* 2005 Jul;19(4):529-33.
60. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI, Kaski JC. *Am J Cardiol.* 2005 Jul 1;96(1):31-4.
61. Mesna ameliorates intestinal mucosa damage after ifosfamide administration in the rabbit at a dose-related manner. Ypsilantis P, Tentes I, Assimakopoulos SF, Kortsaris A, Scopa CD, Simopoulos C. *J Surg Res.* 2004 Sep;121(1):84-91.
62. Dose related effects of ifosfamide on enterocyte apoptosis in different sites of the rabbit intestine. Ypsilantis P, Tentes L, Assimakopoulos SF, Kortsaris A, Scopa CD, Pitiakoudis M, Simopoulos C. *Toxicology.* 2004 Aug 5;200(2-3):135-43.
63. Profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Tziakas DN, Chalikias GK, Parissis JT, Hatzinikolaou EI, Papadopoulos ED, Tripsiannis GA, Papadopoulou EG, Tentes IK, Karas SM, Chatseras DI. *Int J Cardiol.* 2004 Apr;94(2-3):269-77.
64. Subcellular fractionation and electrophoretic analysis of proteins from the regenerating nerve in rabbits following treatment with triiodothyronine (T3). Tentes I, Assimakopoulos B, Hellman U, Nikolettos N, Kortsaris A, Kontoleon-Vakalopoulou E. *In Vivo.* 2003 Nov-Dec;17(6):601-8.
65. Anti-inflammatory cytokine profile in acute coronary syndromes: behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines. Tziakas DN, Chalikias GK, Hatzinikolaou EI, Parissis JT, Papadopoulos ED, Trypsianis GA, Papadopoulou E, Tentes IK, Karas SM, Hatseras DI. *Int J Cardiol.* 2003 Dec;92(2-3):169-75.
66. Matrix metalloproteinases 2 and 9 in follicular fluids of patients undergoing controlled ovarian stimulation for ICSI/ET. Nikolettos N, Assimakopoulos B, Tentes L, Schöpper B, al-Hasani S. *In Vivo.* 2003 Mar-Apr;17(2):201-4.
67. Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein. Koutsodontis G, Tentes I, Papakosta P, Moustakas A, Kardassis D. *J Biol Chem.* 2001 Aug 3;276(31):29116-25.
68. Partial purification and properties of (Na<sup>+</sup> + K<sup>+</sup>)-ATPase from *Potamon potamios*. Tentes I, Stratakis E. *Comp Biochem Physiol C.* 1991;100(3):619-24.